Clinical Trial Update: Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School Study [Phase 3]

View source ↗

Summary

Phase 3 trial update for Dyanavel XR extended-release suspension in children with ADHD, completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Dyanavel XR (amphetamine (extended-release))

Snippet

Sponsor: Tris Pharma, Inc. | Conditions: Attention Deficit Hyperactivity Disorder | Phase 3 | Status: COMPLETED | Results posted: 2019-07-09